Lipigon Pharmaceuticals AB Logo

Lipigon Pharmaceuticals AB

A clinical-stage company developing therapeutics for lipid-related disorders.

LPGO | ST

Overview

Corporate Details

ISIN(s):
SE0015382072
LEI:
549300XPO40YR12SLY87
Country:
Sweden
Address:
Tvistevägen 48 C, 907 36 Umeå

Description

Lipigon Pharmaceuticals is a clinical-stage company specializing in lipid biology, focused on developing novel therapeutics for diseases related to lipid disorders and cardio-metabolic risk factors. The company's lead drug candidate, Lipisense®, is in clinical development for lowering blood triglyceride levels. Lipisense® utilizes a unique mechanism of action to address high blood fats, which are a significant risk factor for cardiovascular disease. The company's pipeline is founded on extensive research in blood lipid regulation, aiming to provide new treatment options for patients with conditions such as severe hypertriglyceridemia and other lipid-related disorders where a significant unmet medical need exists.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Lipigon Pharmaceuticals AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Lipigon Pharmaceuticals AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Lipigon Pharmaceuticals AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-12-16 Johan Living Other Buy 260,000 51,688.00 SEK

Peer Companies

KAZIA THERAPEUTICS LTD Logo
Oncology-focused biotech developing targeted therapies for cancers with high unmet needs.
United States of America
KZIA
Keros Therapeutics, Inc. Logo
Develops protein therapeutics for disorders linked to TGF-β signaling.
United States of America
KROS
Kura Oncology, Inc. Logo
Clinical-stage biopharma company developing precision medicines for cancer treatment.
United States of America
KURA
Larimar Therapeutics, Inc. Logo
A clinical-stage biotech developing treatments for complex rare diseases.
United States of America
LRMR
Lexaria Bioscience Corp. Logo
A biotech company with a patented platform to improve oral drug delivery and absorption.
United States of America
LEXX
LigaChem Biosciences Inc. Logo
Clinical-stage biopharma developing ADCs, immuno-oncology drugs, and small molecules.
South Korea
141080
Linical Co., Ltd. Logo
A global CRO providing a full spectrum of drug development services for biopharma.
Japan
2183
Lipum AB Logo
Clinical-stage biopharma developing novel treatments for chronic inflammatory diseases.
Sweden
LIPUM
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Clinical-stage pharma company developing PP2A inhibitors to enhance cancer therapies.
United States of America
LIXT
Pre-clinical biotech company using AI for drug discovery and biodefense.
United States of America
RENB

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.